Tuesday, KeyBanc has increased the price target on STERIS shares, a provider of infection prevention and other procedural products and services, from $255.00 to $265.00, while maintaining an Overweight rating on the stock. The revision follows recent meetings with the company's management that reinforced the analyst's confidence in STERIS's financial outlook for fiscal year 2025.
The company's management has expressed assurance in achieving its full-year financial targets, including low single-digit growth in Healthcare Capital Equipment. This confidence comes despite some investor skepticism surrounding the company's projections. The management also outlined various factors that support a long-term growth framework ranging from mid single-digit to high single-digit, coupled with a return to more consistent operating margin expansion.
STERIS's approach to capital allocation was also a point of focus during the discussions. The company plans to prioritize organic investments and engage in bolt-on mergers and acquisitions, which are expected to contribute to its long-term financial goals.
The analyst's positive stance on STERIS is based on these insights, suggesting a robust setup for the company's performance in the coming years. The revised price target of $265 reflects the analyst's evaluation of the company's growth prospects and operational strategies.
STERIS's stock price adjustment on the New York Stock Exchange reflects the market's response to the company's strategic plans and the analyst's updated valuation. The Overweight rating indicates that KeyBanc views the company's shares as a favorable investment compared to its sector peers.
In other recent news, STERIS Plc has reported a strong first-quarter performance for 2025, with an 8% increase in total revenue and a 10% rise in adjusted earnings per share to $2.03. The company continues to demonstrate confidence in its services and consumables businesses, despite challenges in the healthcare equipment market.
In addition to this growth, STERIS has announced its 19th consecutive year of dividend increases and unveiled a $100 million restructuring plan aimed at enhancing operations.
The company's net income reached $201.7 million, and its total debt decreased to $2.3 billion. STERIS's outlook for the fiscal year remains positive, with anticipated constant currency organic revenue growth of 6-7%. Adjusted earnings per diluted share are projected to be between $9.05 and $9.25.
However, the company has acknowledged the potential impact of reduced funding and cutbacks in the pharma and bio pharma industries on capital equipment sales. Nevertheless, STERIS is experiencing strong growth in its services and consumables businesses and reported mid-single-digit order growth and a $350 million backlog in the healthcare equipment segment. The company's $100 million restructuring plan is expected to yield most benefits in fiscal year 2026.
InvestingPro Insights
Following KeyBanc's optimistic outlook on STERIS, recent data from InvestingPro supports the positive sentiment. With a solid market capitalization of $23.78 billion, STERIS is a significant player in its industry. The company's commitment to consistent financial performance is evidenced by its impressive revenue growth, which stands at 14.72% over the last twelve months as of Q1 2023. This growth is further complemented by a robust gross profit margin of 43.6%, showcasing the company's efficiency in managing its cost of goods sold.
InvestingPro Tips highlight STERIS's strong track record, including a history of maintaining dividend payments for 20 consecutive years, and the fact that it has raised its dividend for 13 consecutive years. This consistent return to shareholders is a testament to STERIS's financial health and disciplined capital management. Moreover, with analysts predicting profitability this year and the company having been profitable over the last twelve months, investors may find reassurance in STERIS's ability to sustain its financial success.
For those interested in a deeper analysis, InvestingPro offers additional tips on STERIS, which can be accessed at https://www.investing.com/pro/STE. These insights may prove valuable for investors looking to make informed decisions regarding their investments in STERIS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.